Blinatumomab With or Without Revumenib for KMT2A-Rearranged ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests two new drug combinations for a specific type of blood cancer called B-cell acute lymphoblastic leukemia (ALL) that has a genetic change called KMT2A-rearrangement. The goal is to help patients who are at higher risk of their cancer coming back after initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have B-cell acute lymphoblastic leukemia or similar blood cancer with a KMT2A genetic change, confirmed by genetic testing
- Have responded well to initial chemotherapy (fewer than 5% cancer cells in bone marrow)
- Have a sample available to track your cancer cells during treatment, or be able to provide one
- Not have Philadelphia chromosome (a different genetic change) or prior stem cell transplant
- Have acceptable kidney and liver function, heart function, and no uncontrolled infections
- Be able to take oral medications and understand you cannot be pregnant or nursing during the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding a targeted drug (dasatinib or imatinib) to a chemotherapy combination with blinatumomab works better for children and young adults with a specific genetic form of B-cell acute lymphoblastic leukemia. The goal is to see if this approach can improve treatment outcomes for patients with Philadelphia chromosome-positive or ABL-class Ph-like B-ALL.
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
This trial tests a combination of two drugs, blinatumomab and revumenib, for people with a specific kind of acute lymphoblastic leukemia (ALL) that has a change in the KMT2A gene. The goal is to see if the combination works better than either drug alone.
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
This Phase 2 study tests how well blinatumomab works for children and adults whose acute lymphoblastic leukemia (ALL) has come back. It also looks at whether results differ based on the patient’s relapse “risk group.”
This trial tests a sequence of three drugs for adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome. The goal is to see if this approach can better treat the leukemia.
Hear when a new Acute Leukemia of Ambiguous Lineage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.